Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. (Q54494125)

30 May 2018

title

Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. (English)

1 reference

30 May 2018

1 reference

30 May 2018

author name string

Hiroshi Nokihara

1 reference

30 May 2018

Noboru Yamamoto

1 reference

30 May 2018

Yasuhide Yamada

1 reference

30 May 2018

Yosuke Tamura

1 reference

30 May 2018

Kazunori Honda

1 reference

30 May 2018

Yoshitaka Seki

1 reference

30 May 2018

Yuko Tanabe

1 reference

30 May 2018

Hitoshi Shimada

1 reference

30 May 2018

Xiaojin Shi

1 reference

30 May 2018

Tomohide Tamura

1 reference

30 May 2018

publication date

28 July 2012

1 reference

30 May 2018

Investigational New Drugs

published in

1 reference

30 May 2018

volume

1 reference

30 May 2018

issue

1 reference

30 May 2018

page(s)

677-684

1 reference

30 May 2018

Defining the role of mTOR in cancer

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9860-4

Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9860-4

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9860-4

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9860-4

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9860-4

Mechanisms of mTOR inhibitor resistance in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9860-4

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9860-4

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9860-4

Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9860-4

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9860-4

A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22843211

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22843211

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Ethnic differences in drug metabolism and toxicity from chemotherapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22843211

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-012-9860-4

1 reference

30 May 2018

1 reference

30 May 2018